However, the triple therapy did not extend progression-free survival (PFS) beyond the double therapy in postmenopausal women with ER-positive and HER2-negative high-proliferation breast carcinoma (Rugo et al., 2017). This evidence concerns the gene ERBB2 and breast carcinoma.